MANCHESTER, England--(BUSINESS WIRE)--Manchester-based Synexus, a global leader in the recruitment of patients to its own research centres, recruited 2,200 of the 17,802 patients who took part in the recent JUPITER trial presented on Monday 30th March at the ACC*and published in the Lancet. It was the most successful source of patient recruitment providing 13% of participants to just 1% of the 1315 sites taking part in the study.
